Pediatric use of omalizumab for allergic asthma

References

• Bush A, Fleming L. Diagnosis and management of asthma in children. BMJ. 2015;350:h996.
   PubMedGoogle Scholar
• Mazurek JM, Syamlal G. Centers for disease control and prevention. prevalence of asthma, asthma attacks, and emergency department visits for asthma among working adults — national health interview survey, 2011–2016. Morbidity Mortality Weekly Rep. 2018;67(13):377–386; Gibson J, Loddenkemper R, Sibille Y, et al., eds. The European Lung White Book. Respiratory Health and Disease in Europe. Sheffield, European Respiratory Society, 2013.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373.
   PubMed Web of Science ®Google Scholar
• Porcaro F, Cutrera R, Pajno GB. Options of immunotherapeutic treatments for children with asthma. Expert Rev Respir Med. 2019 Oct;13(10):937–949.
   PubMed Web of Science ®Google Scholar
• Licari A, Brambilla I, De Filippo M, et al. The role of upper airway pathology as a co-morbidity in severe asthma. Expert Rev Respir Med. 2017 Nov 11;(11): 855–865. DOI:10.1080/17476348.2017.1381564
   PubMed Web of Science ®Google Scholar
• Marseglia GL, Pagella F, Licari A, et al. Acute isolated sphenoid sinusitis in children. Int J Pediatr Otorhinolaryngol. 2006 Dec;70(12):2027–2031.
   PubMed Web of Science ®Google Scholar
• Licari A, Caimmi S, Bosa L, et al. Rhinosinusitis and asthma: a very long engagement. Int J Immunopathol Pharmacol. 2014 Oct-Dec;27(4):499–508.
   PubMed Web of Science ®Google Scholar
• Guilbert TW, Bacharier LB, Fitzpatrick AM. Severe asthma in children. J Allergy Clin Immunol Pract. 2014;2:489–500.
   PubMed Web of Science ®Google Scholar
• Montella S, Baraldi E, Cazzato S, et al.; Italian Pediatric Severe Asthma Network (IPSAN) on behalf of the Italian Society of Pediatric Respiratory Diseases (SIMRI). Severe asthma features in children: a case-control online survey. Ital J Pediatr. 2016 Jan 22;42:9.
   PubMed Web of Science ®Google Scholar
• Lang A, Carlsen KH, Haaland G, et al. Severe asthma in childhood: assessed in 10-year olds in a birth cohort study. Allergy. 2008;63:1054–1060.
   PubMed Web of Science ®Google Scholar
• Ramratnam SK, Bacharier LB, Guilbert TW. Severe asthma in children. J Allergy Clin Immunol Pract. 2017;5:889–898.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Rasouliyan L, Russo PA, et al.; TENOR Study Group. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy. 2007;62:126–133.
   PubMed Web of Science ®Google Scholar
• Bacharier LB, Guilbert TW, Zeiger RS, et al. Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. J Allergy Clin Immunol. 2009;123:1077–1082.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the national institutes of health/national heart, lung, and blood institute severe asthma research program. J Allergy Clin Immunol. 2011;127:382–389.
   PubMed Web of Science ®Google Scholar
• Just J, Gouvis-Echraghi R, Rouve S, et al. Two novel, severe asthma phenotypes identified during childhood using a clustering approach. Eur Respir J. 2012;40:55–60.
   PubMed Web of Science ®Google Scholar
• Just J, Saint-Pierre P, Gouvis-Echraghi R, et al. Childhood allergic asthma is not a single phenotype. J Pediatr. 2014;164:815–820.
   PubMed Web of Science ®Google Scholar
• Pembrey L, Barreto ML, Douwes J, et al. Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration. ERJ Open Res. 2018;4:00013–2018.
   PubMedGoogle Scholar
• Agache I, Strasser DS, Pierlot GM, et al. Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma. J Allergy Clin Immunol. 2018;141:442–445.
   PubMed Web of Science ®Google Scholar
• Kuo CS, Pavlidis S, Loza M, et al. A transcriptome-driven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED. Am J Respir Crit Care Med. 2017;195:443–455.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–725.
   PubMed Web of Science ®Google Scholar
• Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133(6):1557–63.e5.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45–56.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Simpson JL, Hankin R, et al. Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma. Thorax. 2003;58:116–121.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Henry RL, Thomas P. Noninvasive assessment of airway inflammation in children: induced sputum, exhaled nitric oxide, and breath condensate. Eur Respir J. 2000;16:1008–1015.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–395.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19:977–979.
   PubMed Web of Science ®Google Scholar
• Arasi S, Corsello G, Villani A, et al. The future outlook on allergen immunotherapy in children: 2018 and beyond. Ital J Pediatr. 2018;44:80.
   PubMed Web of Science ®Google Scholar
• Bossley CJ, Fleming L, Gupta A, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol. 2012;129:974–982.
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115(3):459–65 v.
   PubMed Web of Science ®Google Scholar
• He XY, Simpson JL, Wang F. Inflammatory phenotypes in stable and acute childhood asthma. Paediatr Respir Rev. 2011;12:165–169.
   PubMed Web of Science ®Google Scholar
• Douwes J, Gibson P, Pekkanen J, et al. Non-eosinophilic asthma: importance and possible mechanisms. Thorax. 2002;57:643–648.
   PubMed Web of Science ®Google Scholar
• Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168:1308–1311.
   PubMed Web of Science ®Google Scholar
• Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205–217.
   PubMed Web of Science ®Google Scholar
• Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112(6):1147–1154.
   PubMed Web of Science ®Google Scholar
• Holgate S, Smith N, Massanari M, et al. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64(12):1728–1736.
   PubMed Web of Science ®Google Scholar
• Samitas K, Delimpoura V, Zervas E, et al. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. Eur Respir Rev. 2015;24(138):594–601.
   PubMed Web of Science ®Google Scholar
• Redhu NS, Saleh A, Shan L, et al. Proinflammatory and Th2 cytokines regulate the high affinity IgE receptor (FcepsilonRI) and IgE-dependant activation of human airway smooth muscle cells. PLoS One. 2009;4(7):e6153.
   PubMed Web of Science ®Google Scholar
• Roth M, Zhong J, Zumkeller C, et al. The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodelling. PLoS One. 2013;8(2):e56015.
   PubMed Web of Science ®Google Scholar
• Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol. 2012;25(2):475–484.
   PubMed Web of Science ®Google Scholar
• Mauri P, Riccio AM, Rossi R, et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett. 2014;162(1 Pt A):2–10.
   PubMed Web of Science ®Google Scholar
• Riccio AM, Mauri P, De Ferrari L, et al. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. Clin Transl Allergy. 2017 Mar 9;7: 6.
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136:1476–1485.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia G, Castagnoli R, et al. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov. 2015;10(9):1033–1042.
   PubMed Web of Science ®Google Scholar
• Logsdon SL, Oettgen HC. Anti-IgE therapy: clinical utility and mechanistic insights. Curr Top Microbiol Immunol. 2015;388:39–61.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Gallelli L, Renda T, et al. Update on optimal use of omalizumab in management of asthma. J Asthma Allergy. 2011;4:49–59.
   PubMedGoogle Scholar
• Liu J, Lester P, Builder S, et al. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 1995;34:10474–10482.
   PubMed Web of Science ®Google Scholar
• Fox JA, Hotaling TE, Struble C, et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther. 1996;279:1000–1008.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs. 2014;16:491–502.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Panfili E, et al. An update on anti-IgE therapy in pediatric respiratory diseases.Curr Respir Med Rev. 2017 Mar;13(1):22–29.
   PubMed Web of Science ®Google Scholar
• Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155:1828–1834.
   PubMed Web of Science ®Google Scholar
• Boulet LP, Chapman KR, Coˆte J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997;155:1835–1840.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 study group. N Engl J Med. 1999;341:1966–1973.
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–261.
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–190.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr, Nayak A, McAlary M, et al. Omalizumab improves asthma- related quality of life in children with allergic asthma. Pediatrics. 2002;110(5):e55.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124:1210–1216.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005–1015.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol. 2015;26(6):551–556.
   PubMed Web of Science ®Google Scholar
• Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42:1224–1233.
   PubMed Web of Science ®Google Scholar
• Deschildre A, Marguet C, Langlois C, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46:856–859.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Denicolò C, et al. Omalizumab in children with severe allergic asthma: the Italian real-life experience. Curr Respir Med Rev. 2017;13:36–42.
   PubMed Web of Science ®Google Scholar
• Pitrez PM, de Souza RG, Roncada C, et al. Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: a real-life study. Pediatr Pulmonol. 2017;52:1408–1413.
   PubMed Web of Science ®Google Scholar
• Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139:1431–1444.
   PubMed Web of Science ®Google Scholar
• Berger W, Gupta N, McAlary M, et al. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol. 2003;91:182–188.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fowler-Taylor A, Vidaurre CF, et al. Safety and tolerability of omalizumab in children with allergic (IgE- mediated) asthma. Curr Med Res Opin. 2011;27:163–169.
   PubMed Web of Science ®Google Scholar
• Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129:983–989.
   PubMed Web of Science ®Google Scholar
• Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to- severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(560–7):e4.
   Google Scholar
• Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407–412.
   PubMed Web of Science ®Google Scholar
• Wahn U, Martin C, Freeman P, et al. Relationship between pretreat- ment specific IgE and the response to omalizumab therapy. Allergy. 2009;64(12):1780–1787.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125(4):1378–1386.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–811.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573–582.
   PubMed Web of Science ®Google Scholar
• Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy. 2016;71:1472–1479.
   PubMed Web of Science ®Google Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–169.e2.
   PubMed Web of Science ®Google Scholar
• Busse W, Haselkorn T, Rosén K, et al. Greater treatment benefit with omalizumab in children with increased asthma severity: exploratory analyses from the inner- city anti-IgE therapy for asthma (ICATA) Study. J Allergy Clin Immunol. 2018;141(2 Suppl):AB14.
   Web of Science ®Google Scholar
• Sesé L, Schneider M, Bourgoin M, et al. Asthma with multiple allergic comorbidities is associated with complete response to omalizumab. Clin Exp Allergy. 2019;49(5):733–735.
   PubMed Web of Science ®Google Scholar
• Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adoles- cents. J Allergy Clin Immunol Pract. 2013;1:163–171.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Brambilla I, et al. New approaches for identifying and testing potential new anti-asthma agents. Expert Opin Drug Discov. 2018 Jan;13(1):51–63. . Epub 2017 Oct 31. Review. PubMed PMID: 29077521.
   PubMed Web of Science ®Google Scholar
• Licari A, Manti S, Castagnoli R, et al. Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs. 2019 Aug;21(4):215–237.
   PubMed Web of Science ®Google Scholar
• Arasi S, Porcaro F, Cutrera R, et al. Allergy: a pediatric perspective. Front Pediatr. 2019;7:28.28.
   PubMedGoogle Scholar
• Busse WW, Humbert M, Haselkorn T, et al. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2020 Feb;124(2):190–196.
   PubMed Web of Science ®Google Scholar
• Wang KY, Sindher SB, Stinson R, et al. Efficacy and safety of omalizumab in pediatric patients with high immunoglobulin E levels: a case series. Allergy Asthma Proc. 2018;39:289–291.
   PubMed Web of Science ®Google Scholar
• Bourgoin-Heck M, Amat F, Trouvé C, et al. Omalizumab could be effective in children with severe eosinophilic non-allergic asthma. Pediatr Allergy Immunol. 2018;29:90–93.
   PubMed Web of Science ®Google Scholar
• Preventing Asthma in High Risk Kids (PARK). NLM identifier: NCT02808819. [ cited 2020 Jan 19]. Available from: https://clinicaltr ials.gov/ct2/show/NCT02570984
   Google Scholar
• Romano C. Omalizumab therapy for children and adolescents with severe allergic asthma. Expert Rev Clin Immunol. 2015;11:1309–1319.
   PubMed Web of Science ®Google Scholar